Medtronic Closes Acquisition of Affera

Medtronic plc (NYSE, MDT), a Dublin, Ireland-based, multinational healthcare technology company, closed the acquisition of Affera, Inc., Newton, MA-based, medical technology company that specializes in innovative treatments for cardiac arrhythmia. 

This acquisition expands the company’s cardiac ablation portfolio to include its cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution.

The Affera technology, which is used to investigate cardiac arrhythmias or irregular heartbeats such as atrial fibrillation, can provide solutions.

Through this acquisition Medtronic gains the Affera Prism-1™ cardiac mapping and navigation platform, which will be compatible with Medtronic and multiple, competitive therapeutic catheters and technologies. The company also adds the Sphere-9™ cardiac diagnostic and ablation catheter that enables the rapid creation of detailed electro-anatomical maps and delivers radio frequency (RF) and pulsed field (PF) cardiac ablation therapies.

Additional Affera products, such as the Arc-10 Coronay Sin (CS) diagnostic catheter or Sphere PVI Ablation catheter (a single-shot device that delivers pulsed field energy (PFA), are also included.

Led by Doron Harlev, founder and chief executive officer, Affera is a medical technology company dedicated to developing a comprehensive integrated platform to efficiently deliver durable therapy for a broad set of cardiac arrhythmia patients.

The Affera full suite of solutions and technologies will complement the existing Medtronic atrial and ventricular arrhythmia disease management portfolio and support the company’s efforts to offer differentiated, safe, and effective cardiac ablation solutions.

In December 2021, Affera announced the commencement of the recently approved SPHERE Per-AF Trial, a U.S. Food and Drug Administration Investigational Device Exemption pivotal randomized trial, to evaluate the safety and effectiveness of the Affera system for the treatment of persistent AF. Medtronic will continue to support SPHERE Per–AF Pivotal Trial as part of this closure. Affera’s product portfolio is not currently approved or available for sale or commercial use.

FinSMEs

30/08/2022

Leave a Comment